Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Common Equity (2016 - 2025)

Enanta Pharmaceuticals' Common Equity history spans 14 years, with the latest figure at $126.6 million for Q4 2025.

  • For Q4 2025, Common Equity rose 13.21% year-over-year to $126.6 million; the TTM value through Dec 2025 reached $126.6 million, up 13.21%, while the annual FY2025 figure was $64.7 million, 49.76% down from the prior year.
  • Common Equity reached $126.6 million in Q4 2025 per ENTA's latest filing, up from $64.7 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $436.0 million in Q1 2021 to a low of $64.7 million in Q3 2025.
  • Average Common Equity over 5 years is $239.6 million, with a median of $227.3 million recorded in 2023.
  • The largest YoY upside for Common Equity was 13.21% in 2025 against a maximum downside of 49.76% in 2025.
  • A 5-year view of Common Equity shows it stood at $384.4 million in 2021, then fell by 21.74% to $300.8 million in 2022, then tumbled by 36.22% to $191.9 million in 2023, then crashed by 41.73% to $111.8 million in 2024, then rose by 13.21% to $126.6 million in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Common Equity are $126.6 million (Q4 2025), $64.7 million (Q3 2025), and $79.3 million (Q2 2025).